Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis

A Multicenter, Open Label, Pilot Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis (Child-Pugh A5 to A6) and No Response to PR or Prior Failure to First Generation Protease Inhibitors (PIs)

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02732405

Acronym

GECOM

Enrollment

120

Registered

2016-04-08

Start date

2016-05-31

Completion date

2017-03-31

Last updated

2016-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Compensated Cirrhosis, Hepatitis C

Brief summary

To assess efficacy (SVR rate) of MK5172 / MK8742 for 12 weeks without RBV in G1b patients with compensated cirrhosis (Child-Pugh A5 to A6) previously failing first gen. PI or non responders to PR.

Interventions

DRUGMK5172 /MK8742

tablets of MK-5172 100 mg/MK-8742 50 mg will be administered orally, daily for 12 weeks without ribavirin

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Informed consent form signed, 2. Age \> 18 years, 3. Chronic infection with Hepatitis C virus genotype 1b, 4. HCV RNA \> 100 IU/mL, 5. HCV patients previously treated by PR with no response or previously treated with first generation PIs (boceprevir, telaprevir, simeprevir) and failing therapy, 6. Subjects with compensated cirrhosis with Child-Pugh score ranging between A5 to A6. Cirrhosis defined by liver biopsy (METAVIR F4) or non-invasive methods (transient elastography (FibroScan) \> 12.5 KPa; or FibroTest or FibroSure \> 0.75 with APRI \>2), 7. Hepatic Venous Pressure Gradient (HVPG) \> 6 mmHg (only in selected sites), 8. Albumin level ≥ 3.0 g/dl, 9. Platelet count ≥ 75 x 103/μL.

Exclusion criteria

1. Child-Pugh score greater than CP-A6, 2. Patients with HCV genotype 1a, 2, 3, 4, 5, 6, 3. Have any serious or active medical illness which, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance, 4. HIV or chronic hepatitis B virus (HBV) infection (HBsAg positive), 5. Decompensated cirrhosis/previous decompensation, 6. Pregnancy, 7. Breast-feeding, 8. Known hypersensitivity to Grazoprevir, Elbasvir or any of its components, 9. Albumin level \< 3.0 g/dl, 10. Platelet count \< 75 x 103/μl, 11. Concomitant participation in any clinical trial.

Design outcomes

Primary

Measure	Time frame
Sustained virologic response rates 12 weeks after discontinuation of therapy (SVR12). SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.	12 weeks after discontinuation of therapy (SVR12).

Contacts

Primary ContactSavino Bruno, MD

savino.bruno@hunimed.eu

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026